GIA
EGRX

Gargoyle Investment Advisor’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Gargoyle Investment Advisor’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,190
Closed -$221K – 158
2018
Q1 		$221K Buy
+4,190
New +$244K 0.09% 155
2017
Q3 		– Sell
-3,685
Closed -$291K – 199
2017
Q2 		$291K Buy
+3,685
New +$301K 0.12% 154

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Gargoyle Investment Advisor's EGRX Position: Q2 2018 in Review

Gargoyle Investment Advisor sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2018, closing a stake of 4,190 shares — an estimated $221K sold.

Gargoyle Investment Advisor first reported a position in EGRX in Q2 2017 and held it in 2 quarters. The position peaked at $291K in Q2 2017. 183 funds tracked by Wall St. Rank hold EGRX as of Q2 2018.

  • Gargoyle Investment Advisor reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Gargoyle Investment Advisor sold 4,190 Eagle Pharmaceuticals, Inc. shares in Q2 2018, an estimated $221K.
  • Gargoyle Investment Advisor first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
  • Gargoyle Investment Advisor's Eagle Pharmaceuticals, Inc. position peaked at $291K in Q2 2017.
  • 183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2018.

Based on Gargoyle Investment Advisor's 13F filing for Q2 2018, filed 14 Aug 2018.